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Abstract
Aims: To observe the effects of thalidomide on melanoma tumor growth and blood supply
patterns in C57 mice.
Methods: Thirty mice inoculated subcutaneously with B16F10 cells were randomly divided into
the treatment group and the control group. Thalidomide was administered once a day at a dose of
200 mg/kg for the treatment group starting on the fifth day after inoculation, and an equivalent
volume of 0.5% carboxylmethyl cellulose was administered similarly in the control group. The
diameter of the tumors was measured daily after inoculation until the mice were sacrificed on the
19th day. The different blood supply patterns were counted after immunohistochemical and PAS
histochemical double-Staining. VEGF, NF-κB, PCNA, MMP-2 and MMP-9 expression in tumor
tissue was also assessed.
Results: The tumor volume(P = 0.019) and the number of vasculogenic mimicry(P = 0.03) and
mosaic vessels(P = 0.004) in the treatment group were significantly decreased compared with the
control group. VEGF(P = 0.004), NF-κB(P = 0.009), PCNA(P = 0.002), MMP-2 (P = 0.000), MMP-
9(P = 0.002) protein expression and MMP-2(P = 0.000) and MMP-9(P = 0.000) mRNA in the
treatment group were significantly lower than those in the control groups.
Conclusion: Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in
melanoma through the regulation of vasculogenic factors, and it can induce necrosis of melanoma
cells, which may be related with the NF-κB signaling pathway.
Background
Thalidomide was first introduced in the late 1950s for the
prevention of morning sickness in pregnant women, but
it was withdrawn from the market in the 1960s because of
its well-known teratogenicity[1]. Recently thalidomide
has been found to have anti-angiogenesis and anti-
inflammatory properties, and based on these observations
thalidomide has been used as a therapeutic reagent in
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some malignant tumor including liver cancer, renal cell
carcinoma, breast cancer and so on[2]. Many studies also
focused on the effects of thalidomide on metastatic
melanoma. The mechanism of thalidomide against
melanoma maybe attribute to its anti-angiogenic activity.
However, the detail mechanism is still unclear. Except of
endothelium-dependent vessels(EVs), there are vasculo-
genic mimicry (VM) channels and mosaic vessels(MVs) in
melanoma, which constitute the blood supply pattern for
some high-grade malignant tumor [3,4]. In this study we
established a mouse model bearing melanoma tumors
and examined the effect of thalidomide on tumor growth
and angiogenesis patterns.
In 1999, Manitotis et a l[5] described a novel paravascu-
lars tumor blood supply pattern named VM. The VM
channels are lined by tumor cells in the absence of
endothelial cells and fibroblasts, and red blood cells
appear in these channels. There are periodic acid-Schiff
(PAS)-positive extracelluar matrix (ECM) surrounding
these channels or covering on their surface, which may
play important roles in VM formation. Based on microar-
ray analysis, highly aggressive melanoma and less aggres-
sive melanoma differ in the expression of about 210 genes
including some genes associated with the phenotypes of
endothelial and hematopoietic stem cells [6]. Tumor cells
with embryonic-like phenotype have more plasticity, and
can mimic endothelial cells and participate in the forma-
tion of VM channels [7,8]. The expression and secretion of
matrix metalloproteinases (MMPs) also play an impor-
tant role in ECM remodeling. MMP-2 and MMP-9 are
members of MMPs family and they can functionally
degrade collagen IV in ECM, a step essential for tumor
invasion and metastasis[9]. Moreover, MMP-9 generates
growth-proliferating signals and regulates tumor cells pro-
liferation[10]. The mechanism of thalidomide's anti-ang-
iogenic effect may be associated with its teratogenecity
involving with MMPs secretion [11,12]. This paper was
focused on thalidomide influencing different blood sup-
ply patterns formation on animal experiment, and the
related molecular mechanism is also introduced.
Materials and methods
Drug and Animals
Thalidomide was kindly provided by Changzhou Corp. It
was dissolved in 0.5% sodium carboxylmethyl cellulose
(CMC) at a final concentration of 20 mg/ml. Animals
Inbred, clean, black, 6–8 week old C57BL/6 mice were
obtained from Institute of Hematology and Blood Disease
Hospital affiliated Chinese Academy of Medical Sci-
ence(License number: SCXK(Jin)2004-0001). They
arrived in Animal Centre of Tianjin Cancer Hospital one
week before the experiment and were bred under SPF.
This study was approved by the Medical University of
Tianjin's Animal Welfare Committee.
Model of melanoma and tumor experiment in C57 mice
C57BL/6 mice (n = 30) were injected subcutaneously with
2 × 106 murine melanoma B16F10 cells into the lower left
groin. Thirty mice were randomly divided into treatment
group and the control group, with 15 mice in the treat-
ment group and 15 mice in the control group. Thalido-
mide was dissolved in 0.5% sodium carboxyl
methylcellulose. Five days after B16F10 melanoma inocu-
lation, 0.2 ml thalidomide (200 mg/kg/d) was adminis-
tered via interperitoneal injection once a day in the
treatment group and an equivalent volume of 0.5% CMC
alone was administered in the control group. After admin-
istration, there was not obviously symptom of disorder of
digestive tract in the mice of the treatment group. The
length and width of the subcutaneous tumors were meas-
ured using a caliper every day. The tumor size was calcu-
lated according to the following formula: Tumor volume
(cm3) = (length × width2)/2. The tumor growth curve was
drown based on tumor size. On the 19th day after inocula-
tion, all mice were sacrificed, and the tumor tissues were
harvested. Part of the tumor without necrosis were col-
lected and stored at -80°C and the remainder of the
tumors were fixed with formalin and embedded in paraf-
fin.
Real-time PCR to detect MMP-2 and MMP-9 mRNA 
expression levels
Total RNA was extracted with Trizol reagent according to
the manufacturer's instructions. 1% agarose electrophore-
sis and detection of OD260/OD280 ratio were performed
to identify the integration and purity of isolated RNA.
Complementary DNA (cDNA) was synthesized and
amplified from total RNA using the Access real time PCR
system (TaKaRa). The primer sequences used for matrix
metalloproteinase (MMP)-2(GeneID: 17390) detection
were 5'- GATAACCTGGATGCCGTCGTG -3' (sense) and
5'- CTTCACGCTCTTGAGACTTTGGTTC -3' (anti-sense).
The primer sequences used for MMP-9 (GeneID: 17395)
detection were 5'-GCCCTGGAACTCACACGACA-3'
(sense) and 5'-TTGGAAACTCACACGCCAGAAG-3' (anti-
sense). The primers used to amplify β-actin were 5'-CATC-
CGTAAAGACCTCTATGCCAAC-3' (sense) and 5'-
ATGGAGCCACCGATCCACA-3' (antisense). The resultant
cDNA products of MMP-2, MMP-9 and β-actin were 109,
86 and 174 base pairs, respectively. Real time PCR prod-
ucts were analyzed with the Gene AMP PCR System 5700
Sequence Detector and the CT values were evaluated. The
CT value (the cycle number at which the fluorescence
crosses the threshold) was determined and 2ΔCT where
ΔCT = ΔCTMMPs-ΔCTβ-actin was defined as the relative quan-
tity of the amplified fragment. Every sample was tested in
triplicate and the mean value was used. The products of
real-time PCR were validated with 1.5% agarose electro-
phoresis.Journal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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Histopathological examination and Immunohistochemical 
staining
For histopathology studies, tumor tissues were cut in the
center to obtain the largest section and indicate the infor-
mation of the whole tumor. They were then fixed in 10%
buffered formalin, dehydrated, and embedded in paraffin
using routine methods. For immunohistochemical stain-
ing, formalin-fixed, paraffin-embedded tissue was sec-
tioned and dried overnight at 65°C and deparaffinized in
xylene. The sections were rehydrated through graded alco-
hols into water. Endogenous peroxidase was blocked with
3% hydrogen peroxide in 50% methanol for 10 min at
room temperature. After rehydrating, the sections were
washed with PBS and then pretreated with citrate buffer
(0.01 M citric acid, pH 6.0) for 20 min at 100°C in a
microwave oven. After rinsing with PBS, slides were incu-
bated overnight at 4°C with primary polyclonal antibod-
ies (rabbit anti-human, mouse and rat), including the
antibodies against vascular endothelial growth fac-
tor(VEGF), proliferating cell nuclear antigen(PCNA)
(Boster Biological technology Ltd, Wuhan, China, dilu-
tion 1:150), nuclear factor-κB (NF-κB, Upstate, New York,
USA, dilution 1:100), MMP-2 (BA0596, Boster Biological
technology Ltd, Wuhan, China, dilution 1:100), and
MMP-9 (BAO573, Boster Biological technology Ltd,
Wuhan, China, dilution 1:100). The sections were then
washed with PBS and incubated with the second antibody
for 30 min at 37°C. The sections were incubated with sec-
ondary antibody (Non-Biotin HRP detection system,
Zhongshan goden bridge biotechnology CO., Ltd, Beijing,
China) for 30 min at 37°C after the PBS washes. Visuali-
zation was performed using a DAB Kit(DC 10, Boster Bio-
logical technology Ltd, Wuhan, China) under microscope.
The nuclei were counterstained with hematoxylin, fol-
lowed by dehydration and coverslip mounting. Appropri-
ate positive and negative controls without primary
antibody were included.
Immunohistochemical and PAS histochemical double-
Staining methods
Antibodies used in this study were mouse monoclonal
anti-CD34 (Sigma Chemical Co., St. Louis, Mo, USA) and
mouse monoclonal anti-HMB45(BM0093, Boster Biolog-
ical technology Ltd, Wuhan, China, dilution), which were
used at dilutions: 1:400. After immunohistochemical
staining, Sections were exposure to 1% sodium periodate
for 10 min. The sections were then rinsed with distilled
water for 5 min and incubated with periodic acid-Schiff
(PAS) for 15 min. Finally, all of the sections were counter-
stained with hematoxylin, dehydrated and mounted. Nor-
mal human stomach mucous membrane was the positive
control.
Quantification of determination of the positive ratio for 
VEGF, NF-κB, PCNA, MMP-2, MMP-9 and microvessel 
patterns count
When stained for VEGF, NF-κB, MMP-2 and MMP-9,
tumor cells with brown cytoplasm were considered posi-
tive, and when stained for PCNA, tumor cells with brown
nuclei were considered positive. We observed 10 fields per
section at 400× magnification, and positive cell numbers
were counted in 100 random melanoma cells in every
field. The mean percentage of positive cells was used to
determine the expression of the proteins in a section. EVs,
MVs and VM channels were also counted. All these counts
were blindly performed in at least 3 randomly chosen sec-
tions from each mouse. The mean value of each type of
microvessel in 10 fields was the final outcome.
Statistical analysis
Statistical software SPSS 10.0 (Chicago, Illinois) was used
in the analysis. A P value less than 0.05 was considered
statistically significant. Two-way ANOVA was performed
to evaluate melanoma growth of two groups. Counts of
distinguished blood vessels in the treatment group and
the control group were evaluated with one-way ANOVA.
Differences of protein and mRNA expressions between
two groups were compared using an unpaired t test.
Results
Effects of thalidomide on growth of melanoma
Ninth days after melanoma cell injection, engrafted
tumors were palpated on the mouse groin areas and
detected tumors were removed. Soft globular tumors were
observed and there were numerous network vessels on the
tumor surfaces. Some melanoma cells invaded into the
skeletal muscle and showed a spindle configuration. The
engrafted melanomas in the thalidomide treatment group
grew slower than those in the control group (Figure 1).
Fourteen days after the thalidomide administration, the
average size of the tumor in the treatment group was
6.912 cm3, while in the control group it was 4.164 cm3.
The tumor volume in the treatment group was decreased
compared with the control group and there was statistical
significance between these two groups (P = 0.019) after
the mice were sacrificed. In the early stages of the experi-
ment, there were no significant differences in tumor vol-
ume, but from day 12 to day 19 the tumor volume in the
treatment group showed a obvious reduction compared
with the control group (Figure 1 and Figure 2A). There
were large areas of necrosis in tumor tissues of the treat-
ment group, while necrosis was not obvious in the control
group. Numerous melanoma cells of the treatment group
were characterized as cell degeneration including vacuoles
within the cytoplasm and nuclei. However, in the control
group, there are only some tumor cell degeneration in the
centre of tumor mass.Journal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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Results of immunohistochemical and PAS histochemical 
double-Staining methods
We performed PAS staining and staining for the endothe-
lial cell markers CD34. CD34 is a marker of endothelial
cells and the base membrane is positive for PAS. CD34
immunohistochemical and PAS histochemical double-
staining was used to distinguish VM, MVs and EVs.
HMB45 immunohistochemical and PAS histochemical
double-Staining was used to identify the origin of tumor
cells lining VM channels and the structure of VM as well.
Cells lining VM channels were negative for CD34 and pos-
itive for HMB45 confirmed that cells around the channels
were not composed of endothelium but melnaoma cells
(Figure 2B and 2C). Some channels lined with both
CD34-positive/PAS positive and HMB45-positive/PAS
positive cells were MVs. Red cells in the centre of VM chan-
nels indicated that they may be connected with EVs.
Under microscope with 400× magnification, EVs, MVs
and VM channels were counted and the three microcircu-
lation patterns could co-exist in melanoma(Figure 2D).
The number of VM(P = 0.03) and MVs(P = 0.004) in the
treatment group were decreased compared with the con-
trol group. There were fewer EVs in the treatment group
compared with the control group, but the difference was
not statistically significant (P = 0.068) (Table 1).
Effects of thalidomide on B16F10 melanoma growth Figure 1
Effects of thalidomide on B16F10 melanoma growth. Error bars represent standard deviations for the experimental 
and the control groups. In the early stages of the experiment, there are no significant differences in tumor volume, but from 
day 12 to day 19 the tumor volume in the treatment group showed a clear reduction compared with the control group. There 
is statistical significance between these two groups when the mice are sacrificed (P = 0.019).Journal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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Inhibition of VEGF, NF-κB, PCNA, MMP-2 and MMP-9 
expression by thalidomide
Both the treatment group and the control group con-
tained positive tumor cells. The positive positions of
tumor cells for VEGF, NF-κB, MMP-2 and MMP-9 staining
were located in the cytoplasm and for PCNA in the
nucleus. VEGF(P = 0.004), NF-κB(P = 0.009), PCNA(P =
0.002), MMP-2(P  = 0.000), and MMP-9(P  = 0.002)
expression in the treatment group was significantly
decreased compared with the control group, including
overall number and staining intensity of the positive cells
(Figure 3 and Table 2). The number of tumor cells positive
for PCNA staining in the treatment group was less than
observed in the control group. Results of PCNA immuno-
histochemical staining indicated that the tumor cells in
the treatment group had a lower proliferative ability than
that in the control group.
Results of Real-time PCR
Real time PCR demonstrated that the expression of MMP-
2 mRNA in the treatment group was decreased compared
with the control group, which was similar to MMP-2,
Different microcirculation patterns in melanoma tissue of murine xenograft model Figure 2
Different microcirculation patterns in melanoma tissue of murine xenograft model. A. Tumor volume in the con-
trol group was larger than in the treatment group, suggesting thalidomide inhibits tumor growth. B. VM channel (red arrow) 
was formed by tumor cells and there were red cells in the center of the channels. PAS-positive substances lined these channels 
and formed basement membrane-like structure. Yellow arrow indicated EVs presenting in the same field with VM. Endothelial 
cells were stained as brown by immunohistochemical staining for CD 34, CD34 and PAS double-Staining, 1000×. C. Red arrow 
showed a VM channel that was lined by brown melanoma cells as well as pink PAS-positive substances. Melanoma cells were 
identified by HMB45 antibody. HMB45 and PAS double-Staining, 400×. D. In the control group, mitosis was present and VM 
channels were more numerous under low-magnify field. H&E, 200×.Journal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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MMP-9 protein expression. The CT value of MMP-2 and
MMP-9 in the control group was lower than that in the
treatment group. The results of real time PCR show that
thalidomide could down-regulate MMP-2 and MMP-9
mRNA expression, suggesting that thalidomide can
inhibit tumor growth via down-regulation of the MMP-2
and MMP-9 mRNA level(Table 3). There were statistical
significance for MMP-2(P  = 0.000) and MMP-9(P  =
0.000) mRNA levels between the treatment group and the
control group.
Discussion
Malignant melanoma is one kind of the most aggressive
form for skin malignant tumor. Malignant melanoma has
proven to be highly resistant to conventional chemother-
apy and operation is still the main therapeutic method for
melanoma. Patients with malignant melanoma generally
have a high risk of recurrence and a short survival
time[13]. Thalidomide was withdrawn from the market
due to its teratogenecity, but in recent years its use has
been focused on its anti-angiogenic property[1,14-16].
Thalidomide has been used in phase II trials as a treat-
ment for solid cancers such as renal cell cancer and hepa-
tocellular carcinoma where it has shown significant anti-
tumor effects [17,18]. It has been proposed that the tera-
togenic property of thalidomide involves in the produc-
tion of reactive oxygen species (ROS), leading to
subsequent DNA damage[5]. Thalidomide generates ROS
that affect differentiation of murine embryonic cells dur-
ing vasculogenesis and angiogenesis in the embryo
[19,20]. When thalidomide-induced ROS formation is
inhibited, the anti-angiogenesis properties of thalidomide
will be reduced.
It had been believed that EVs are the only microcircula-
tion mechanism present in tumors for a long time, so
endothelium are the target of the traditional anti-angio-
genesis treatment for solid tumors [21,22]. However, VM,
an endothelium-independent microcirculation pattern,
has been demonstrated to exist in many malignant tumor
types. These findings suggest that the VM channel should
be an additional target in an anti-angiogenesis strategy to
treat solid tumors [23-27]. A result of cDNA microarray
from Seftor EA et al [7,8] confirmed that highly aggressive
melanoma cells with VM expressed more embryonic-like
genes, while they were absent in poorly aggressive ones.
Hence thalidomide targeting at embryo angiogenesis and
anti-vasculogenesis may exert its influence on VM chan-
nels formation though inhibiting embryonic-like geno-
type.
VM channels, MVs and EVs coexist in melanoma and con-
tribute to the melanoma blood supply in the B16
melanoma model[28]. The presence of VM channels, and
MVs not only meet the need for oxygen and nutrients
required for tumor growth but also enhance tumor metas-
tasis. In this study VM channels and MVs were signifi-
cantly decreased in the treatment group compared with
the control group. This phenomenon may be related to
the anti-angiogenesis and anti-VM formation property of
thalidomide. One feature of VM formation is that the
tumor cells join together to form an extracellular matrix-
rich network contributing to a paravascular system that
coexists with endothelium-lined vessels. In addition,
MMP family members, especially MMP-2 and MMP-9,
play important roles in endothelium-dependent vessels
and VM channel formation[29]. Collagen IV is a major
constituent of basement membrane ECM and a major
function of MMP-2 and MMP-9 is to degrade collagen IV
resulting in promotion of angiogenesis. Furthermore,
MMP-9 can induce VEGF to be secreted into ECM result-
ing in enhanced tumor angiogenesis[8,30].
In this report, tumor growth in the treatment group was
significantly decreased compared with the control group.
Results of our study agreed with the idea that inhibition of
tumor growth by thalidomide was dependent on the
blockage of angiogenesis. It has been reported that thalid-
omide inhibits angiogenesis by interrupting processes
mediated by vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF)[31]. Thalido-
mide has also been described as an inhibitor of TNF
alpha, probably by enhancing the degradation of TNF
alpha mRNA[32]. VEGF, known as a vascular permeabil-
ity factor that enhances vascular permeability and pro-
motes new vessel growth, was thought to be one of the
factors responsible for angiogenesis[33]. In this study,
VEGF expression in the treatment group was decreased
compared with that in the control group, suggesting that
the mechanism of thalidomide inhibiting tumor angio-
Table 1: Comparison of the mean number of three microcirculation patterns between the treatment group and the control group (  
± SD)
Control (n = 15) Experimental (n = 15) t P
VM channels 1.86 ± 0.89 0.58 ± 0.37 3.08 0.030
MVs 0.90 ± 0.45 0.33 ± 0.19 3.54 0.004
Endothelium- dependent vessel 2.22 ± 1.52 0.54 ± 0.37 2.44 0.068
* SD: Standard Deviation
xJournal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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genesis maybe related with reducing VEGF expression.
Furthermore, NF-κB has been found to have anti-apopto-
sis, pro-angiogenesis, and pro-metastasis properties. Tha-
lidomide inhibits H2O2-induced NF-κB activation[34]. In
this study, NF-κB and PCNA expression were also
decreased in the thalidomide treatment group compared
with those in the control group. These data suggest that
NF-κB also play important role in thalidomide preventing
tumor cell proliferation, angiogenesis.
Three factors govern the formation of functional and pat-
terned microcirculation channels by VM: (1) plasticity of
highly malignant tumor cells, (2) remodeling of the ECM,
and (3) the connection of the VM channel and host blood
vessels to acquire a blood supply from the host tissue[24].
Matrix metalloproteinases (MMPs) can cleave one or sev-
eral constituents of the extracellular matrix (ECM) [30].
MMPs can degrade ECM which facilitates vascular forma-
tion and tumorigenesis. A key step of VM formation is that
MMPs secreted by tumor cells digest ECM and remodelled
of ECM. The remodeling of ECM has been correlated with
MMP overexpression. Highly aggressive melanoma cells
have the ability to secrete MMPs and degrade ECM in
vitro[8]. In our experiment, the expression of MMP-2 and
MMP-9 was decreased in the treatment group compared
with the control group. Thalidomide may inhibit MMP-2
and MMP-9 expression and thereby inhibit VM channel
formation.
In this report, we demonstrated that the effect of thalido-
mide on the microcirculation patterns in the B16F10
Figure 3
Immunohistochemical staining results of VEGF, NF-κB, MMP- 2, MMP-9, and PCNA Figure 3
Immunohistochemical staining results of VEGF, NF-
κB, MMP-2, MMP-9, and PCNA. VEGF, NF-κB, PCNA, 
MMP-2, MMP-9 protein expression including the number and 
staining intensity of positive cells in the treatment group 
were significantly lower than those in the control groups. A. 
VEGF expression in the control group. Tumor cells showed 
brown cytoplasmic staining. IHC, 400×. B. VEGF expression 
in the treatment group. IHC, 400×. C. NF-κB expression in 
the control group. Tumor cells showed brown cytoplasmic 
staining. The immune reaction in the nuclear was rare in this 
study. IHC, 400×. D. NF-κB expression in the treatment 
group. IHC, 400×. E. MMP-2 expression in the control group. 
Tumor cells showed brown cytoplasmic staining. IHC, 200×. 
F. MMP-2 expression in the treatment group. IHC, 200×. G. 
MMP-9 expression in the control group. Tumor cells showed 
brown cytoplasmic staining. IHC, 200×. H. MMP-9 expres-
sion in the treatment group. IHC, 200×. I. PCNA expression 
in the control group. Tumor cells showed brown nuclear 
staining. IHC, 200×. J: PCNA expression in the treatment 
group. IHC, 200×.
Table 2: Comparison of the mean percentage of positive cells for 
VEGF, NF-κB, PCNA, MMP-2 and MMP-9 expression between 
the treatment group and the control group (  ± SD)
Control (n = 15) Experimental (n = 15) t P
VEGF 18.34 ± 2.32 13.67 ± 2.51 3.47 0.004
NF-κB 17.92 ± 4.45 12.21 ± 2.84 3.05 0.009
MMP-2 24.06 ± 3.92 10.93 ± 3.35 2.36 0.000
MMP-9 19.32 ± 3.66 10.46 ± 3.76 2.31 0.002
PCNA 80.94 ± 4.90 67.55 ± 7.75 2.18 0.002
* SD: Standard Deviation
xJournal of Experimental & Clinical Cancer Research 2008, 27:60 http://www.jeccr.com/content/27/1/60
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mouse melanoma involved inhibition of microcircula-
tion formation and protein expression. In this experi-
ment, The dose of thalidomide we used at 200 mg/kg/day
is comparable to 4 mg/kg/day in humans that is a safe
level without serious side effects[35]. Thalidomide pro-
moted B16F10 melanoma cell necrosis and inhibited
VEGF, NF-κB, PCNA, MMP-2 and MMP-9 expression. EVs,
MVs and VM channels contributed to the microcirculation
patterns in the B16F10 melanoma model described in this
report. The presence of the three microcirculation patterns
not only meets the need for oxygen and nutrients required
for tumor growth but also enhance metastasis. MMP fam-
ily members, especially MMP-2 and MMP-9, play impor-
tant roles in EVs, MVs and VM channel formations. These
data provide a basis for considering thalidomide for use in
the treatment of solid tumors with VM.
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